Historique
Article de Périodique
Cannabis antagonists: a new era of social psychopharmacology? (2005)
(Les antagonistes du cannabis : une nouvelle ère de la psychopharmacologie sociale ?)
Auteur(s) :
NUTT, D.
Année
2005
Page(s) :
3-4
Sous-type de document :
Editorial
Langue(s) :
Anglais
Refs biblio. :
6
Domaine :
Drogues illicites / Illicit drugs
Résumé :
The recent announcements by Synthelabo-Sanofi that their cannabis (CB1) receptor antagonist Rimonabant has shown efficacy in treating obesity and improving lipid profiles, as well as in assisting in smoking cessation (Anthenelli and Despres, 2004), suggests that we are about to enter a new era of psychopharmacology. For the first time, we will have an antagonist to the most highly expressed G-protein coupled receptor in human brain - there are more CB1 receptors in brain than the total of all dopamine, serotonin and noradrenaline receptors combined. Despite the discovery of endogenous cannabinoids over a decade ago, the role of these receptors has not been clear, although the advent of antagonists and the development of CB1 knockout mice have begun to clarify this question.
Affiliation :
The Psychopharmacology Unit, University of Bristol, Dorothy Hodgkin Building, Whiston Street, Bristol BS1 3NY.
Royaume-Uni. United Kingdom.
Royaume-Uni. United Kingdom.
Cote :
A02908